Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (September 2026)
16 slides from Avicanna's investor presentation, September 2026
Slide 1: A Biopharmaceutical Leader in Cannabinoid-Based Medicine
A Biopharmaceutical Leader in Cannabinoid-Based Medicine Q3 2026 TSX: AVCN OTCQX: AVCNF FSE: 0NN avicanna.com
Slide 2: Disclaimer & Notice Regarding Forward Looking Statements
DISCLAIMER & NOTICE REGARDING FORWARD LOOKING STATEMENTS Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regula
Slide 3: Integrated Cannabinoid-Based Biopharmaceutical Platform
Integrated Cannabinoid-Based Biopharmaceutical Platform A vertically integrated platform spanning API, R&D, clinical development, and patient care Commercial & Medical Platform Medical Cannabis Products (RHO Phyto™) • 4 integrated commercial-stage business units • 50+ proprietary commercialized cann
Slide 4: Rho Phyto
Rho PhytoTM Pharmaceutical-grade cannabinoid formulations Standardized cannabinoid formulations across multiple delivery systems Proprietary drug delivery systems designed to enhance bioavailability and dosing precision Supported by pre-clinical, clinical, and real-world evidence Developed for Clini
Slide 5: QUIX Nanotechnology Rapid Onset
ay iD RAPID ONSET OX). NANOTECHNOLOGY QUIX™ is a scientific platform enabling faster onset, superior bioavailability and next-generation cannabinoid products RHO Phyto” POWE RED BY QUIX NANOTECHNOLOGY — | / RH Rapid Act Gummies lax Bhyton J QUIX Sour White Grape 25 THC & ar POWERED By ‘ ummies / 4 L
Slide 6: MyMedi.ca | Nationwide Medical & Commercial Infrastructure
MyMedi.ca™ | Nationwide Medical & Commercial Infrastructure A proprietary platform enabling patient access, real-world evidence, and commercialization of cannabinoid-based therapies Strategic Value • Direct engagement with patients,prescribers, and payers • Real-world evidence generation platform •
Slide 7: Six Integrated Pillars of Medical Cannabis Care
Six Integrated Pillars of Medical Cannabis Care A complete platform designed around the patient journey and the healthcare ecosystem.
Slide 8: Avicanna Academy | Medical Affairs & Clinical Education Platform
Avicenna Academy | Medical Affairs & Clinical Education Platform Supporting the integration of cannabinoid-based therapies into clinical practice Core Capabilities • Healthcare practitioner education and training • Indication-specific clinical insights and case studies • Scientific exchange and rese
Slide 9: Pharmaceutical Pipeline | Indication-Specific Cannabinoid Therapeutics
Pharmaceutical Pipeline | Indication-Specific Cannabinoid Therapeutics Leveraging an integrated platform to develop proprietary, evidence-based drug candidates Formulation Medical Clinical & Pharmaceutical Technologies Platform Real-World Data Pipeline Major Target Clinical Areas Sleep Epilepsy Anxi
Slide 10: Pharmaceutical Pipeline | Status
Pharmaceutical Pipeline | Status Program Indications Formulation Preclinical RWE Clinical Registration Development TruneroxTM Gastaut Syndrome & Approved, Oral CBD Oil TBD AVCN226908 Dravet Syndrome Colombia AVCN319301a Oral CBD/THC Osteoarthritic Pain & AVCN319301b SEDDS Capsules Oral THC Solid AVC
Slide 11: Global Commercial Platform | International Expansion
Global Commercial Platform | International Expansion Expanding cannabinoid-based pharmaceutical and medical products across Commercial Presence and Potential • 24 international markets served, across all continents • Scalable platform supported by integrated API and manufacturing capabilities • Plat
Slide 12: Established Scientific Platform & Institutional Validation
Established Scientific Platform & Institutional Validation Supporting the development of evidence-based cannabinoid therapeutics Scientific Platform 50+ 10+ • Proprietary formulation and delivery technologies • Clinical and pre-clinical research programs • Real-world evidence generation through MyMe
Slide 13: Financial Highlights | 2025 Performance
Financial Highlights | 2025 Performance Strong margins, improving profitability, and disciplined capital structure $25.5M 53% ($0.29M) Adjusted EBITDA 0 Debt Revenue Gross Profits (near breakeven) on the Balance Sheet Profitability & Efficiency • Significant improvement in EBITDA performance • Expan
Slide 14: Management and Board of Directors
Management and Board of Directors Senior Management Team Board of Directors Aras Azadian Aras Azadian Founder and CEO Founder and CEO Nick Hilborn Lisa McCormack Interim Chief Financial Officer Independent Director Stephen Kim Ozgur Kilic Chief Legal Officer & General Counsel Independent Director Iv
Slide 15: Investment Highlights
Investment Highlights Supporting the development of evidence-based cannabinoid 1. Integrated Platform End-to-end capabilities spanning API, R&D, clinical research, and patient access 2. Pharmaceutical Pipeline Indication-specific cannabinoid drug candidates across dermatology, pain, sleep, anxiety a
Slide 16: Thank You
Thank You Q3 2026 TSX: AVCN OTCQX: AVCNF FSE: 0NN avicanna.com info@avicanna.com